Welcome to LookChem.com Sign In|Join Free
  • or
N-ethylpiperidine-3-carboxamide is a chemical compound with the molecular formula C8H16N2O. It is a white crystalline solid that is soluble in water and various organic solvents. N-ethylpiperidine-3-carboxamide is primarily used as an intermediate in the synthesis of pharmaceuticals, particularly in the production of certain analgesics and anti-inflammatory drugs. Its structure consists of a piperidine ring with a carboxamide group at the 3-position and an ethyl group at the nitrogen atom. Due to its potential applications in the pharmaceutical industry, N-ethylpiperidine-3-carboxamide has been the subject of research and development efforts to optimize its synthesis and explore its therapeutic properties.

4138-28-7

Post Buying Request

4138-28-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4138-28-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 4138-28-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,1,3 and 8 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 4138-28:
(6*4)+(5*1)+(4*3)+(3*8)+(2*2)+(1*8)=77
77 % 10 = 7
So 4138-28-7 is a valid CAS Registry Number.

4138-28-7Upstream product

4138-28-7Downstream Products

4138-28-7Relevant academic research and scientific papers

SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

-

Page/Page column 100-101, (2012/10/08)

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.

INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA

-

Page/Page column 67, (2009/07/18)

The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 4138-28-7